SAN
DIEGO, Sept. 7, 2023 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders,
today announced that the company will participate at two
upcoming investor conferences.
Details of the company's participation are as follows:
- H.C. Wainwright 25th Annual Global Investment
Conference
Details: Brian
Lian, Ph.D., Viking's chief executive officer, will deliver
a corporate presentation
Conference Dates: September 11-13,
2023
Presentation Timing: 12:30 – 1:00
p.m. Eastern on Tuesday, September
12, 2023
Location: Lotte New York Palace Hotel
- Morgan Stanley 21st Annual Global Healthcare
Conference
Details: Dr. Lian will participate in a fireside
chat
Conference Dates: September 11-13,
2023
Fireside Chat Timing: 7:30 – 8:00
a.m. Eastern on Wednesday, September
13, 2023
Location: Sheraton New York
A live webcast of the H.C. Wainwright presentation may be
accessed via a link on the Viking Therapeutics website in the
Investors & Media section under Webcasts. Additionally, a
replay of the webcast will be available on the Viking website
following the conferences.
About Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical
company focused on the development of novel first-in-class or
best-in-class therapies for the treatment of metabolic and
endocrine disorders, with three compounds currently in clinical
trials. Viking's research and development activities leverage
its expertise in metabolism to develop innovative therapeutics
designed to improve patients' lives. The company's clinical
programs include VK2809, a novel, orally available, small molecule
selective thyroid hormone receptor beta agonist for the treatment
of lipid and metabolic disorders, which is currently being
evaluated in a Phase 2b study for the treatment of
biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis.
In a Phase 2a trial for the treatment of non-alcoholic fatty liver
disease (NAFLD) and elevated LDL-C, patients who received VK2809
demonstrated statistically significant reductions in LDL-C and
liver fat content compared with patients who received placebo. The
company is also developing VK2735, a novel dual agonist of the
glucagon-like peptide 1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) receptors for the potential
treatment of various metabolic disorders. Data from a Phase 1 trial
evaluating VK2735 (dosed subcutaneously) for metabolic disorders
demonstrated an encouraging safety and tolerability profile as well
as positive signs of clinical benefit. The company also recently
initiated a Phase 1 study to evaluate an oral formulation of
VK2735. In the rare disease space, the company is developing
VK0214, a novel, orally available, small molecule selective thyroid
hormone receptor beta agonist for the potential treatment of
X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently
being evaluated in a Phase 1b clinical trial in patients
with the adrenomyeloneuropathy (AMN) form of X-ALD. The company
holds exclusive worldwide rights to a portfolio of five therapeutic
programs, including VK2809 and VK0214, which are based on small
molecules licensed from Ligand Pharmaceuticals Incorporated.
For more information about Viking Therapeutics, please
visit www.vikingtherapeutics.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-at-upcoming-investor-conferences-301919893.html
SOURCE Viking Therapeutics, Inc.